ONWARD Medical Appoints Ali Kiboro as Chief Financial Officer
MWN-AI** Summary
ONWARD Medical N.V., a pioneering neurotechnology company focused on spinal cord stimulation therapies, has appointed Ali Kiboro as its Chief Financial Officer, effective January 2026. With over 25 years of experience in financial leadership within the medical technology sector, Kiboro joins ONWARD from AliveDx, where he played a significant role in the company's financial strategy and operational transformation. His previous experience includes senior finance positions at Quest Diagnostics and General Motors, showcasing a diverse managerial background that aligns well with ONWARD's growth objectives.
Dave Marver, CEO of ONWARD Medical, expressed enthusiasm about Kiboro's appointment, emphasizing his capacity to drive growth within life science companies, critical for ONWARD's current development phase. In his new role, Kiboro acknowledged the company's momentum, highlighting its mission and unique technology platforms, which promise significant advancements in restoring movement and function for individuals with spinal cord injuries.
ONWARD Medical is at the forefront of developing innovative therapies to enhance independence for individuals with movement disabilities. The company’s proprietary ARC Therapy has earned multiple Breakthrough Device Designations from the FDA and its ARC EX® System is already available for commercial sale in the U.S. and Europe. Furthermore, ONWARD is working on an investigational implantable system, ARC-IM®, intended to address unmet needs in post-spinal cord injury care and potentially integrate with brain-computer interfaces.
Headquartered in the Netherlands, ONWARD also has a Science and Engineering Center in Switzerland and a U.S. office in Boston. The company is listed on multiple European exchanges and OTCQX in the U.S. As it progresses, ONWARD aims to remain at the cutting edge of neurotechnology, dedicated to restoring quality of life for the spinal cord injury community.
MWN-AI** Analysis
The recent appointment of Ali Kiboro as Chief Financial Officer of ONWARD Medical N.V. should be viewed positively by investors in the neurotechnology space. With over 25 years of experience in financial leadership across medical sectors, Kiboro’s background in scaling life science companies suggests he is well-equipped to aid ONWARD in its ambitious growth trajectory. His previous successes at AliveDx, Quest Diagnostics, and General Motors indicate a strong ability to navigate complex financial landscapes, making him a valuable asset as ONWARD advances its innovative therapies for spinal cord injuries and related motor disabilities.
ONWARD Medical is making strides in developing proprietary technologies, notably ARC Therapy, which has already gained FDA Breakthrough Device Designations. This regulatory achievement positions the company favorably in a competitive, fast-evolving market. The ARC EX® System’s clearance for commercial sale both in the US and Europe provides a significant revenue generation opportunity, especially as awareness and demand for innovative treatment options expand. Investors might anticipate enhanced financial strategy and operational transformation under Kiboro’s guidance, potentially leading to improved market performance.
Moreover, ONWARD’s exploration of an investigational implantable system, ARC-IM®, and its integration with artificial intelligence and brain-computer interface technology may attract further attention and investment. The combination of clinical efficacy and technological innovation could set ONWARD apart in a burgeoning market.
However, investors should remain cautious of inherent risks associated with the healthcare sector, including regulatory challenges, competitive pressures, and market demand fluctuations. The long-term success of ONWARD Medical will largely depend on its capacity to innovate, execute its strategy effectively, and deliver on investor expectations. Therefore, while the stock presents potential upside, it’s critical for investors to stay informed about regulatory developments and market dynamics surrounding the company’s product offerings.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
EINDHOVEN, the Netherlands, Jan. 23, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the neurotechnology company pioneering spinal cord stimulation therapies to restore movement, function, and independence, today announces the appointment of Ali Kiboro as Chief Financial Officer, effective January 2026.
Ali brings more than 25 years of financial leadership experience across medical technology, tools and diagnostics, and general industry. He joins ONWARD Medical from AliveDx (formerly Quotient Limited, a NASDAQ-listed company) where he served as Chief Financial Officer, leading the company’s financial strategy, capital markets activities, and operational transformation. Prior to AliveDx, Ali held a variety of senior finance leadership roles at Quest Diagnostics and General Motors.
“We are delighted to welcome Ali Kiboro to our leadership team,” said Dave Marver, Chief Executive Officer of ONWARD Medical. “Ali’s experience driving growth and scaling life science companies make him a strong addition to ONWARD at this important stage.”
“I am excited to join ONWARD Medical at a time of significant momentum,” said Ali Kiboro. “ONWARD’s purpose-driven mission, unique technology platforms, and fast progress across innovation and commercial fronts position the company well for the future. I look forward to contributing to its long-term success.”
Ali holds an MBA in Finance from The Wharton School of the University of Pennsylvania and a Bachelor of Science in Finance, summa cum laude, from Duquesne University.
About ONWARD Medical
ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities. Building on decades of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed its proprietary ARC Therapy. It has subsequently been awarded 10 Breakthrough Device Designations from the FDA. The Company’s ARC EX® System is cleared for commercial sale in the US and Europe. The Company is also developing an investigational implantable system called ARC-IM®, designed to address several unmet needs including blood pressure instability after spinal cord injury. It can also be paired with a brain-computer interface (BCI) and artificial intelligence (AI) to restore thought-driven movement.
Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY).
To learn more about ONWARD Medical’s commitment to partnering with the spinal cord injury community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit ONWD.com.
To be kept informed about the Company’s technologies, research studies, and the availability of therapies in your area, please complete this webform.
For Media Inquiries:
Sébastien Cros, VP Communications
media@onwd.com
For Investor Inquiries:
investors@onwd.com
Disclaimer
Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited.
FAQ**
How does the appointment of Ali Kiboro as CFO affect the financial strategy and growth trajectory of Onward Medical N ONWRY, particularly in light of its innovative ARC Therapy?
What specific developments in the ARC-IM system does Onward Medical N ONWRY plan to pursue under Ali Kiboro’s financial leadership?
Considering the 10 FDA Breakthrough Device Designations, how does Onward Medical N ONWRY envision leveraging Ali Kiboro's experience to enhance its market position?
What are the key upcoming milestones for Onward Medical N ONWRY that could impact investor sentiment and financial performance in light of recent leadership changes?
**MWN-AI FAQ is based on asking OpenAI questions about Onward Medical N (OTC: ONWRY).
NASDAQ: ONWRY
ONWRY Trading
0.0% G/L:
$4.84 Last:
1,048 Volume:
$4.84 Open:
